Proliferative Diabetic Retinopathy
Conditions
Keywords
vitrectomy
Brief summary
This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.
Interventions
DRUGproactive Anti-VEGF (conbercept) use
preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
DRUGpassive Anti-VEGF (conbercept) use
No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
Sponsors
Peking University Third Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* PDR patients undergoing vitrectomy
Exclusion criteria
* patients who had received intravitreal injection or systemic use of all types of anti-VEGF agents in the recent three months before vitrectomy * patients who had received intravitreal injection or systemic use of all types of steroid in the recent one month before vitrectomy * patients who had received complete PRP before vitrectomy * patients who are pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rate of postvitrectomy complication | 6 months | postvitrectomy DME, VH (recurrent or nonabsorbent), NVG |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| postvitrectomy BCVA | 6 months | BCVA at 1,3,6 month after vitrectomy |
Countries
China
Contacts
Primary ContactHuijin Chen, Dr.
Outcome results
None listed